Biography

• Dr. Jiang has about 18 years of working experiences in the field of cancer biotherapy. She is responsible for the research and development of antibody and CAR T cells against solid tumor. Dr. Jiang has published more than 20 SCI papers in journals such as the Journal of the National Cancer Institute, Clinical Cancer Research; Cancer Immunology Research, Molecular Therapy, Journal of Immunology, The Journal of Biological Chemistry, etc. She firstly explored the Claudin18.2 CAR T cells antitumor efficacy on the gastric cancer and the EGFR/EGFRvIII bitargeted CAR T cells effect on the glioblastoma as the first author. She also as the co­corresponding author to publish the world's first paper on the combination therapy of small molecule and CAR T cells for the treatment of hepatocellular carcinoma. She undertakes more than 10 research projects as the project director, including the Programs of the National Natural Science Foundation of China, Supporting Programs of Shanghai Science and Technology Innovation Action Plan, etc. She declared more than 40 invention patents including 15 authorized patents of the United States, Europe, Japan, Korea, etc. international patent authorization. She was awarded the honorary of "Shanghai Rising-Star (A type)" and “Shanghai Technology Research Leader”.

• Dr. Jiang earned her Bachelor's degree in Clinical Medicine from Jining Medical College in 2001. She obtained Master's degree in Pathogen Biology from Shandong University in 2004 and M.D. & Ph.D. in Pathogen Biology from Fudan University in 2007.

Publications:

1. Min Zhou, Muhua Chen, Bizhi Shi, Shengmeng Di, Ruixin Sun, Hua Jiang*, Zonghai Li*. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling. doi: https://doi.org/10.1016/j.ymthe.2022.07.021. (*Co-corresponding Author)

2. Yansha Sun, Yiwei Dong, Ruixin Sun, Yifan Liu, Yi Wang, Hong Luo, Bizhi Shi, Hua Jiang*, Zonghai Li*. Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors. Mol Ther Oncolytics. 2022, 25:160–173. (*Co-corresponding Author)

3. Sun R, Luo H, Su J, Di S, Zhou M, Shi B, Sun Y, Du G, Zhang H, Jiang H*, Li Z*. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther. 2021; 29(1):60-74. (*Co-corresponding Author)

4. Luo H, Su J, Sun R, Sun Y, Wang Y, Dong Y, Shi B, Jiang H*, Li Z*. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion. Clin Cancer Res. 2020; 26(20):5494-5505. (*Co-corresponding Author)

5. Hua Jiang#, Zhimin Shi#, Peng Wang, Cong Wang, Linlin Yang, Guoxiu Du, Honghong Zhang, Bizhi Shi, Jie Jia, Qixiang Li, Huamao Wang, Zonghai Li*. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019; 111(4):409-418.

6. Xiuqi Wu, Hong Luo, Bizhi Shi, Shengmeng Di, Ruixin Sun, Jingwen Su, Ying Liu, Hua Li, Hua Jiang*, Zonghai Li*. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Mol Ther. 2019; 27(8):1483-1494. (*Co-corresponding Author)

7. Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z*, Jiang H*. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. J Immunol. 2019; 203 (1):198-207.

8. Hua Jiang, Huiping Gao, Juan Kong, Bo Song, Peng Wang, Bizhi Shi, Huamao Wang and Zonghai Li*. Selective targeting of glioblastoma with EGFRvIII/EGFR bi-targeted chimeric antigen receptor T cell. Cancer Immunol Res. 2018, 6(11):1314-1326.

9. Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H*. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII expressing glioblastoma in C57BL/6 mice. Biomed Pharmacother. 2019; 113:108734.

10. Dong Q, Shi B, Zhou M, Gao H, Luo X, Li Z, Jiang H*. Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12. Front Med. 2019; 13(1):83-93.

11. Hua Jiang, Bo Song, Peng Wang, Bizhi Shi, Qixiang Li, Mingliang Fan, Shengmeng Di, Jie Yang, Zonghai Li*. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. Protein & Cell. 2017, 8(12): 926–931.

12. Xiuqi Wu, Bizhi Shi, Jiqin Zhang, Zhimin Shi, Shengmeng Di, Minliang Fan, Huiping Gao, Hai Wang, Jianren Gu, Hua Jiang*, Zonghai Li*. A fusion receptor as a safety switch, detection and purification biomarker for adoptive transferred T cells. Mol Ther. 2017, 25(10): 2270-2279. (*Co-corresponding Author)

13. Hua Jiang, Qiongna Dong, Xiaoying Luo, Bizhi Shi, Huamao Wang, Huiping Gao, Juan Kong, Jiqin Zhang, Zonghai Li. The Monoclonal Antibody CH12 augments 5-fluorouracil-induced Growth Suppression of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III, Cancer Letter. 2014，342(1):113-120.

14. Yaqiong Yang#, Hua Jiang#, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao and Zonghai Li*. The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III. Neoplasia. 2012,14(6): 509-518. (#Co-first Author)

15. Hua Jiang, Huamao Wang, Zhonghua Tan, Suwen Hu, Hai Wang, Bizhi Shi, Lin Yang, Peiyong Li, Jianren Gu, Hongyang Wang, and Zonghai Li*. Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III. J Biol Chem. 2011, 286: 5913-5920.